6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2020

Commission File Number 000-50112

RepliCel Life Sciences Inc.

(Translation of registrant's name into English)

Suite 900 - 570 Granville Street, Vancouver, British Columbia  V6C 3P1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

SUBMITTED HEREWITH

Exhibit	Description
99.1	News Release dated November 27, 2020
99.2	Material Change Report dated November 27, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RepliCel Life Sciences Inc.

/s/ Lee Buckler                            

Lee Buckler, President

Date: November 30, 2020

EX-99.1

NEWS RELEASE

RepliCel Announces Filing of Amended and Restated
Financial Statements and Management Discussion & Analysis

VANCOUVER, BC, CANADA - November 27, 2020 - RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the Company has determined, on the recommendation of the Audit Committee of the Company's Board of Directors (the "Audit Committee") and after consultation with BDO Canada LLP, the Company's independent registered public accounting firm, that the Company's previously issued audited financial statements for the years ended December 31, 2019 and 2018 and the unaudited interim financial statements for third quarter of 2018, the first, second and third quarters of 2019, and the first and second quarters of 2020, as filed on SEDAR, and with the U.S. Securities and Exchange Commission on Form 6-K, will be restated in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and should no longer be relied upon.

RepliCel management was recently notified by BDO Canada LLP of a potential error in previously audited and unaudited interim financial statements. Management and the Audit Committee has now concluded that an error was made in how a contingent liability included in the Company's 2018 License and Collaboration Agreement with YOFOTO (China) Health Industry, Co. (the "Agreement") was measured and recorded. The error and required restatements pertain to that fact that the put liability included in the Agreement was measured as a derivative liability rather than at the present value of the exercise price of the put.  The put was initially determined to have $nil value for the purposes of the Company's financial statements however management has now determined that the initial present value of the exercise price upon issuance was $520,000.  In subsequent periods, the put liability will be recorded at amortized cost.

It has now been determined that as of July 10, 2018, the date the Company entered in to the Agreement, the Company's:

• contract asset was understated by approximately $100,000;
• contract liability was understated by approximately $1,000,000;
• put obligation was understated by approximately $520,000; and
• common shares and warrants recorded in equity were overstated by approximately $1,420,000.

It has now been determined that for the reporting periods subsequent to July 10, 2018, the:

• reported license revenue was understated in each period;
• accretion expense related to the put liability was understated; and
• amortization expense related to the contract asset was understated.

1 | Page

It has now been determined that for the year ended December 31, 2018, cash flows from operating activities were understated by approximately $1,000,000 and cash flows from financing activities were overstated by the same amount.

The Company intends to amend, restate and refile the audited financial statements and related management discussion and analysis for the years ended December 31, 2019 and 2018.  The Company will not be filing amended and restated interim financial statements but will address the correction in the Company's interim financial statements for the three and nine month period ended September 30, 2020 and in the restated and refiled December 31, 2019 and 2018 audited financial statements.

A copy of the amended and restated financial statements and management discussion and analysis for the years ended December 31, 2019 and 2018 and a copy of the interim financial statements and management discussion and analysis for the three and nine month period ended September 30, 2020 will be posted on the Company's website and filed under the Company's profile on SEDAR at www.sedar.com.

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration.  These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function.

The Company's product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RepliCel has also developed a proprietary injection device, RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications. RCH-01 is currently being co-developed with, and under exclusive license by, Shiseido for certain Asian countries. All product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.

For more information, please visit www.replicel.com or contact:
Lee Buckler, CEO and President
604-248-8693

Info @replicel . com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

2 | Page

EX-99.2

51-102F3
MATERIAL CHANGE REPORT

Item 1Name and Address of Company

RepliCel Life Sciences Inc. ("RepliCel" or the "Company")
900 - 570 Granville Street
Vancouver, BC  V6C 3P1

Item 2Date of Material Change

November 27, 2020

Item 3News Release

The news release dated November 27, 2020 was disseminated through Market News and Stockwatch.

Item 4Summary of Material Change

On November 27, 2020, the Company announced that the Company has determined, on the recommendation of the Audit Committee of the Company's Board of Directors (the "Audit Committee") and after consultation with BDO Canada LLP, the Company's independent registered public accounting firm, that the Company's previously issued audited financial statements for the years ended December 31, 2019 and 2018 and the unaudited interim financial statements for third quarter of 2018, the first, second and third quarters of 2019, and the first and second quarters of 2020, as filed on SEDAR, and with the U.S. Securities and Exchange Commission on Form 6-K, will be restated in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and should no longer be relied upon.

RepliCel management was recently notified by BDO Canada LLP of a potential error in previously audited and unaudited interim financial statements. Management and the Audit Committee has now concluded that an error was made in how a contingent liability included in the Company's 2018 License and Collaboration Agreement with YOFOTO (China) Health Industry, Co. (the "Agreement") was measured and recorded. The error and required restatements pertain to that fact that the put liability included in the Agreement was measured as a derivative liability rather than at the present value of the exercise price of the put.  The put was initially determined to have $nil value for the purposes of the Company's financial statements however management has now determined that the initial present value of the exercise price upon issuance was $520,000.  In subsequent periods, the put liability will be recorded at amortized cost.

It has now been determined that as of July 10, 2018, the date the Company entered in to the Agreement, the Company's:

• contract asset was understated by approximately $100,000;
• contract liability was understated by approximately $1,000,000;
• put obligation was understated by approximately $520,000; and
• common shares and warrants recorded in equity were overstated by approximately $1,420,000.

It has now been determined that for the reporting periods subsequent to July 10, 2018, the:

• reported license revenue was understated in each period;
• accretion expense related to the put liability was understated; and

• amortization expense related to the contract asset was understated.

It has now been determined that for the year ended December 31, 2018, cash flows from operating activities were understated by approximately $1,000,000 and cash flows from financing activities were overstated by the same amount.

The Company intends to amend, restate and refile the audited financial statements and related management discussion and analysis for the years ended December 31, 2019 and 2018.  The Company will not be filing amended and restated interim financial statements but will address the correction in the Company's interim financial statements for the three and nine month period ended September 30, 2020 and in the restated and refiled December 31, 2019 and 2018 audited financial statements.

A copy of the amended and restated financial statements and management discussion and analysis for the years ended December 31, 2019 and 2018 and a copy of the interim financial statements and management discussion and analysis for the three and nine month period ended September 30, 2020 will be posted on the Company's website and filed under the Company's profile on SEDAR at www.sedar.com..

Item 5Full Description of Material Change

5.1Full Description of Material Change

A full description of the material change is described in Item 4 above and in the News Release which was filed on SEDAR at www.sedar.com.

5.2Disclosure for Restructuring Transactions

N/A

Item 6Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7Omitted Information

None

Item 8Executive Officer

Contact:Lee Buckler, CEO and President
Telephone:604.248.8693

Item 9Date of Report

November 27, 2020